Since pentoxifylline substantially reduces the β-catenin activity in melanoma cells, this drug might be useful in induction of the melanoma response to CTLA-4, PD-L1 and PD-1 blockade in a subset of patients with the WNT/ β-catenin pathway-driven exclusion of the host immune response. Here, CTLA4 is linked to melanoma.